Apptly Announces $1,000,000 Non-Brokered Private Placement 
SATO Technologies Corp. Announces Loan Settlement Eliminating All of Its Senior Secured Debt and C$1.5 Million Private Placement 
Theralase(R) Closes C$3.6 Million Brokered Financing Intercept Pharmaceuticals to Present at J.P. Morgan 41st Annual Healthcare Conference on January 12, 2023
MORRISTOWN, N.J., Jan. 05, 2023 (GLOBE NEWSWIRE) — Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical…
ShapeTX to Showcase Groundbreaking Advances in CNS in vivo RNA Editing, CNS-Targeting AAVs, and TruStable™ AAV Manufacturing at the J.P. Morgan 41st Annual Healthcare Conference
SEATTLE, Jan. 05, 2023 (GLOBE NEWSWIRE) — ShapeTX today announced Francois Vigneault, Ph.D., Co-founder and…
Black Diamond Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass. and NEW YORK, Jan. 05, 2023 (GLOBE NEWSWIRE) — Black Diamond Therapeutics, Inc….
Revolo Biotherapeutics Completes Enrollment in Phase 2 Trial of ‘1104 in Allergic Disease
Topline data anticipated in Q2 2023 NEW ORLEANS and LOS ANGELES and LONDON, Jan. 05,…
Paratek Pharmaceuticals Receives $36.4 Million Milestone Payment Associated with the Second Procurement of NUZYRA® (omadacycline) under BARDA Project BioShield Contract
Total Procurement-related Revenue Recognition of $38.1 Million to Paratek in December 2022 Procurement Triggered by…
Volta Medical Secures €36M in Series B Funding to Support Adoption of its AI Software for Cardiac Ablation, New CFO Introduced
New round of financing led by Vensana Capital will support technology platform expansion and further…
Noema Pharma to Attend and Present at 41st Annual J.P. Morgan Healthcare Conference in San Francisco
BASEL, Switzerland and BOSTON, Jan. 05, 2023 (GLOBE NEWSWIRE) — Noema Pharma, a clinical-stage biotech…
MBX Biosciences to Present at the 41st Annual J.P. Morgan Healthcare Conference
CARMEL, Ind., Jan. 05, 2023 (GLOBE NEWSWIRE) — MBX Biosciences, Inc., a clinical stage biopharmaceutical…
Salarius Pharmaceuticals Announces Issuance of New U.S. Patent for Next-Generation Targeted Protein Degraders
Expands intellectual property portfolio with composition-of-matter patent protection for second novel molecular glue Protein degrader…
AltruBio to Present at Biotech Showcase™ 2023
SAN FRANCISCO, Jan. 05, 2023 (GLOBE NEWSWIRE) — AltruBio Inc. (“AltruBio” or “the Company”), a…
Vaxxinity to Present at the 2023 J.P. Morgan Healthcare Conference
DALLAS, Jan. 05, 2023 (GLOBE NEWSWIRE) — Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering…
Minovia Therapeutics appoints Maha Radhakrishnan, Chief Medical Officer at Biogen, as board member
TIRAT HACARMEL, Israel, Jan. 05, 2023 (GLOBE NEWSWIRE) — Minovia Therapeutics (Minovia), a clinical-stage company focused on…
F2G to Present at Biotech Showcase™ 2023
MANCHESTER, United Kingdom, Jan. 05, 2023 (GLOBE NEWSWIRE) — F2G Ltd. today announced that the…
Surface Oncology Announces First Patient Dosed in a Phase 1/2 Study Evaluating SRF114, a Potential Best-In-Class Anti-CCR8 Antibody, in Patients with Advanced Solid Tumors
SRF114 is designed to preferentially deplete CCR8+ Treg cells within the tumor microenvironment and has…
Sensei Biotherapeutics Announces Clinical Supply Agreement with Regeneron for Phase 1/2 Clinical Trial Evaluating SNS-101, a Conditionally Active VISTA-blocking Antibody, in Combination with Libtayo® (cemiplimab) in Solid Tumors
BOSTON, Jan. 05, 2023 (GLOBE NEWSWIRE) — Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company…
Frontier Medicines Advances First Development Candidate, FMC-376, a Uniquely Differentiated Inhibitor of Both Active and Inactive KRASG12C, into IND-Enabling Studies
FMC-376 directly, rapidly, and completely blocks both active and inactive forms of KRASG12C to overcome…
InflaRx Provides Update on Planned Phase III Study Design in Pyoderma Gangrenosum with Vilobelimab and Status of its EUA Application in Critically Ill COVID-19 Patients
Multi-national, randomized, controlled adaptive Phase III design for vilobelimab in ulcerative pyoderma gangrenosum (PG) Trial…
Biogen Names Priya Singhal as Executive Vice President, Head of Development
CAMBRIDGE, Mass., Jan. 05, 2023 (GLOBE NEWSWIRE) — Biogen Inc. (Nasdaq: BIIB) announced that Priya…
Arbutus Announces 2023 Corporate Objectives and Provides Financial Update
Data from multiple Phase 2a clinical trials combining AB-729 with other compounds expected in 2023…
Intellia Therapeutics Highlights Strategic Priorities and Anticipated 2023 Key Milestones
Strategic priorities focus on late-stage development of its CRISPR-based medicines while continuing to expand and…